Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.  The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients.

"Patients with Alzheimer's disease have a number of symptomatic therapies available to them. However, the effects of the available medications are modest. Even if significant progress is made in slowing disease progression, more effective therapies that sustainably improve the cognition of the patients are clearly needed," said Kees Been, EnVivo president and CEO. "There is growing consensus that alpha-7 nicotinic agonists can potentially improve the cognitive function in Alzheimer's disease patients as evidenced by the number of large pharmaceutical companies advancing similar drugs through development. The potential upside for patients is considerable and we look forward to completing our Alzheimer's disease study by the middle of next year."

The Phase IIb study will enroll mild to moderate Alzheimer's disease patients who will be randomized to three separate doses of EVP-6124 or placebo over six months. Efficacy will primarily be determined by the ADAS-Cog scale, a commonly used and accepted measure of cognition in patients with Alzheimer's disease. Secondary assessments will include other cognitive and clinical measures. EVP-6124 also is being tested in patients with schizophrenia in a separate Phase IIb study that started in late 2009
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... Frederick, MD (PRWEB) , ... ... ... software is a class-leading frozen sample management solution, indispensable to any modern ... web-based application that has a user-friendly interface. Users know precisely where a ...
(Date:7/23/2015)... ... July 23, 2015 , ... One hundred years ago ... 1915 National Model Aeroplane Competition, with hopes of winning the Henry S. Villard Trophy. ... centennial. , Participants will have the opportunity to build a Free Flight fantasy club ...
(Date:7/23/2015)... 23, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), are pleased to ... Drug (IND) Application with the U.S. Food and ... BHV-0223. Portage holds 54% equity interest in Biohaven, ... glutamate modulating agent and Biohaven has entered into ...
(Date:7/23/2015)... MIAMI (PRWEB) , ... July 23, 2015 , ... ... stem cell research in Santiago, Chile. The symposium will feature some of the ... a full day of high-level scientific discussion for medical professionals in general practice. , ...
Breaking Biology Technology:RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 2Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 3
... Polymer nano-films and nano-composites are used in a ... sports equipment to automotive and aerospace applications. Thermal ... these applications, but the growing trend to use ... In recent years an atomic force microscope-based ...
... N.J., Jan. 12, 2012 NeoStem,s cell therapy ... Inc. company (NYSE Amex: NBS ) ... whereby PCT will provide contract manufacturing and regulatory ... – PTM, which will be an injectable suspension ...
... the way pavement, softened by a hot sun, will ... with wondrous propertiesslows down an object sliding across its ... slippery, say theorists at the National Institute of Standards ... the material,s friction. "I don,t think anyone expects ...
Cached Biology Technology:Magnetic actuation enables nanoscale thermal analysis 2Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 2Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 4Slippery when stacked: NIST theorists quantify the friction of graphene 2
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... LEDs to light UT arena . . . ... the University of Tennessee,s Thompson-Boling Arena will become the ... smaller, brighter and up to 85 percent more efficient ... fixtures developed by Oak Ridge-based LED North America incorporate ...
... peninsula of 11,500 km2 within the Arabian Peninsula. Both ... last decades, thus putting a strong pressure on native ... development has triggered a variety of studies of its ... confirmed the occurrence of 21 lizard species, two of ...
... bone marrow cells to deliver potentially curative gene therapy ... syndrome an often fatal condition that causes organ ... Children,s Hospital Medical Center and the National Institute of ... for treating the disease the week of Feb. 3-7 ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, February 2014 2Story tips from the Department of Energy's Oak Ridge National Laboratory, February 2014 3Where do lizards in Qatar live? First distribution maps for the state 2Mouse study shows gene therapy may be possible cure for Hurler syndrome 2
... Kit measures adenosine triphosphate (ATP) ... a dynamic range. Based on ... measures ATP in bacterial, plant ... concentration range of 10-11 to ...
... of refrigerated cold traps offers a choice ... volatility/aqueous solvents or high volatility solvents. Ideal ... concentrators/centrifugal evaporators. Also used for maintaining vapor-free ... used in electron microscopes. Can be used ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
Black 96 Well Plate EB, RE Bottom...
Biology Products: